Use of docetaxel for treating cancers
AssigneeAventis Pharma S.A.
InventorsCharles L. Vogel, Robert E. Bellet
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating cancer, comprising administering a dose of docetaxel and a dose of rhuMAb HER2 to a patient in need thereof, wherein said dosages have a synergistic therapeutic effect when compared to the administration of docetaxel or rhuMAb HER2 alone.
Claims16
A method of treating a cancer that expresses a HER2/proto-oncogene, comprising administering docetaxel and rhuMAb HER2 to a patient in need thereof, wherein said compounds have a synergistic therapeutic effect when compared to the administration of docetaxel or rhuMAb HER2 alone.
A synergistic therapeutic pharmaceutical combination, comprising docetaxel at a dose of approximately 20 to 100 mg/m2, and rhuMAb HER2 at a dose of approximately 2 to 10 mg/kg.
Dependencies are inferred from the claim text.